ABSTRACT To determine the effect of calcium-channel blockers on 13-adrenergic receptors, we studied the interactions of verapamil, diltiazem, and nifedipine with both human lymphocyte 132 547-554, 1985. 
IMPORTANT differences in clinical effects are apparent between the Food and Drug Administration-approved calcium-channel blockers verapamil, diltiazem, and nifedipine. This difference is evident in the pharmacologic effects of these agents. For example, both nifedipine and verapamil reduce blood pressure in hypertensive subjects. However. nifedipine is associated with an increase in heart rate and stroke index,' whereas verapamil may cause a reduction in heart rate and stroke index.2 The reason for these differences is not clear but is not surprising considering the marked structural differences between these agents. It has been suggested that these agents may act at different calcium channels (reviewed in ref. 3) . Additionally, it has been appreciated that verapamil and related compounds may interact at sites other than calcium chan-Tissue preparation. Whole blood was taken from healthy volunteers according to a modification of previously described methods.' Lymphocytes were isolated from ethylenediamine tetra-acetate acid (EDTA)-anticoagulated blood according to the method of Boyum. Fresh blood (100 ml) was centrifuged at 300 g for 14 min at room temperature, the platelet-rich plasma was aspirated, and the buffy coats were collected into two 50 ml tubes and diluted approximately fourfold with 30 ml of phosphate-buffered saline (pH 7.6). A Ficoll (6%) Hypaque (10%) solution was carefully subfused and the samples centrifuged at 400 g for 40 min at room temperature. After careful removal of the saline/plasma layer, the lymphocyte band was harvested by aspiration. The mononuclear cells isolated by this procedure were at least 80% small lymphocytes.
The lymphocytes were washed with ice-cold buffer containing 100 mM NaCl, 15 mM MgCl2, 3 mM EDTA, 6 mM sucrose, and 20 mM Tris-HCI (pH 7.9 at room temperature) and centrifuged at 37,000 g for 10 min. The supernatant was discarded and the pellet was resuspended in an ice-cold Ilysing" buffer of 3 mM EDTA and 2 mM Tris-HCl (pH 7.9 at room temperature) and homogenized with a Polytron, setting 7, for 10 sec. The homogenate was centrifuged at 37,000 g for 10 min. The pellet from this centrifugation was demonstrated morphologically to contain no intact cells. For binding studies, the preparations were resuspended in 20 mM Tris-HCI, 15 mM MgCl2, 3 mM EDTA, and 100 mM NaCl (pH 7.9 at 250 C) at a concentration of 200 to 300 g.g protein/ml and frozen and stored at -800 C. Storage for up to 10 Aliquots of the lymphocyte or cardiac cell preparations containing 10 to 20 ,ug of protein were incubated with various concentrations of ICYP in a final volume of 250 gl containing 0.5 mM ascorbic acid, 1.0 gg bovine serum albumin, 12 mM Tris-HCl (pH 7.9, 24°C), 60 mM NaCI, 9 mM MgCl2, 1.8 mM EDTA, and 3.6 mM sucrose. Samples were incubated in disposable polypropylene tubes at 370 C for 100 min, at which time steady state had been reached at all concentrations. Incubations were stopped by the addition of 10 ml of 0.9% NaCl with 10 mM Tris-HCI and 15 mM MgCl2 (pH 7.9 at 250 C) to each assay tube followed by separation of membrane-bound and "free" ICYP by rapid filtration through Whatman GF/C filters. Each filter was washed with an additional 10 ml of buffer and radioactivity was determined in a gamma counter. Protein concentration was determined by the method of Lowry et al., 10 with bovine serum albumin as a standard.
ICYP bound selectively to 13-adrenergic We demonstrated that competition curves for the agonist isoproterenol in the absence of added guanine nucleotides were ".shallow," with a slope factor less than 1, and were best fit to a two affinity state model. These data suggest heterogeneous binding of agonists to the leukocyte 13-receptor. This is not caused by the presence of multiple 83-receptor subtypes, since the lymhocyte 1l-receptor population is primarily of the 132-subtype. These data are consistent with the ternary complex model of the 18-receptor, i.e., that the receptor binds agonists with two affinities, high and low. 12 1' According to this model, formation of the "high affinity complex" is a prerequisite for /3-receptor-mediated adenylate cyclase activity. An impaired ability to form the high-affinity complex has been correlated with reduced 13-adrenergic adenylate cyclase activity (so-called uncoupling of the 13-receptor complex) as in the phenomenon of desensitization. 13 Changes in the ability to form the high-affinity complex can be inferred from changes in the competition curves for agonists (e.g., isoproterenol).'3 By means of computerized fitting of isoproterenol competition curves, an impaired ability to form the high-affinity state has been correlated with reductions in the computer-derived estimates for the proportion of receptors binding agonist with a high affinity (%RH) and for the ratio of the dissociation constants of the high-and lowaffinity states (KL/KH).'3Therefore, to study the effect of verapamil treatment on the ability to form the high-affinity complex of the 1-receptor, we performed agonist competition curves with lymphocyte membranes from subjects given verapamil.
With the addition of Gpp(NH)p the fit of isoproterenol competition curves was not significantly improved by assuming a two-affinity state model. This is consistent with the results of previous studies, suggesting that addition of guanine nucleotides in vitro converts the receptor population to a homogeneous low-affinity state. 13 Therefore the IC50 for isoproterenol competition in the presence of added guanine nucleotides solely represents the low-affinity state of the receptor for agonists.
In initial studies we showed that competition curves for the antagonist propranolol were steeper (slope factor approaching 1) and were best explained by a one affinity site model. This suggests that for the lymphocyte /3-receptor, as in other model systems, an antagonist binds with one homogeneous affinity, not dependent on guanine nucleotides. 13
Receptor density and KD for the antagonist radioligand ICYP were determined from saturation curves of specific ICYP Schild plots for verapamil and norverapamil inhibition of isoproterenol-stimulated adenylate cyclase activity were constructed from concentration-response curves, each with six concentrations of isoproterenol either with no inhibitor or at three concentrations of each inhibitor. The EC50 was determined from logit analysis of the dose-response curves of isoproterenol-stimulated adenylate cyclase activity. The dose ratio was determined at each concentration of verapamil or norverapamil, i.e., the EC50 for isoproterenol-stimulated adenylate cyclase activity at each concentration of the inhibitor was divided by the EC50 for isoproterenol in the absence of inhibitor. From the plot of log dose ratio-1 vs log inhibitor concentration, the antilog of the x-intercept is the A2, a measure of how potently the drug inhibits isoproterenol-stimulated adenylate-cyclase activity.
All experiments described were performed on three to six different occasions.
Subject protocol. To determine the effect of verapamil on leukocyte /-receptor regulation in man, we studied six healthy male subjects before, during, and after treatment with verapamil.
Subjects were between 20 and 33 years of age and had no abnormality on routine history and physical examination and were normotensive. All were drug free for at least 3 days before study. Subjects were studied on three occasions: before treatment, after 1 week of verapamil treatment (120 mg three times daily), and at least 4 days after discontinuing verapamil. All subjects remained in bed overnight in the University of Iowa Clinical Research Center. Before 7 A.M. and before rising, an indwelling catheter was inserted; 20 min later a 100 ml blood sample was drawn. Blood samples were analyzed for plasma norepinephrine by high-performance liquid chromatography-electrochemical detection and for verapamil and norverapamil by high-performance liquid chromatography-fluorescence detection (Bio-Science, Bellwood, IL). Radioligand binding studies and assays for adenylate cyclase activity were performed as described above. Maximal ,B-adrenergic-mediated adenylate cyclase activity was determined at a 100 ,uM concentration of isoproterenol. Maximal nonreceptor-stimulated activity was determined with 3 mM NaF.
The statistical significance of differences between study periods was determined by analysis of variance followed by Student's t test for paired data or Wilcoxon signed ranks test (where appropriate); p < .05 in a two-sided test was taken as the minimum level of significance.
Results
In the lymphocyte broken cell preparation, verap- we would expect that long-term administration of verapamil would result in /3-receptor "up-regulation"
analogous to that observed with long-term administration of propranolol. We also found that norverapamil, the major metabo-lite of verapamil, had a much higher affinity for the /3-receptor than the parent compound. In vivo, long-term verapamil administration was associated with increased lymphocyte /3-adrenergic-mediated adenylate cyclase activity. This appears to be related to an increase in receptor affinity for agonists without a corresponding increase in antagonist binding (that is, an increase in the Bmax or a decrease in the KD for ICYP). It is notable that the increase in /-receptor affinity for isoproterenol was not associated with an increase in RH/RL or in KL/KH and was also demonstrated in the presence of Gpp(NH)p. Thus the increase in affinity of the recognition site of the receptor for isoproterenol is caused by a shift of both the high-and low-affinity states of the receptor for agonist. Therefore the associated increase in ,3-adrenergic-mediated adenylate cyclase activity cannot be caused simply by an increased ability to form the high-affinity complex (according to the ternary complex model'2' 13). Alterations in the low-affinity state have been reported in other studies of human leukocyte /3-receptor regulation.26 27 However, the molecular explanation for these changes is unclear. The increase in receptor affinity for agonist with verapamil treatment is not caused by persistent verapamil in the membrane preparation, since this would have caused an artifactual reduction in receptor affinity for isoproterenol.
The reduction in plasma norepinephrine levels seen with verapamil administration was unexpected. Theoretically, verapamil might have been expected to mediate an increase in plasma norepinephrine through its effect as a presynaptic a2-adrenergic receptor antagonist.4' 28 However, we have found the reverse situation.
Assuming the reduction in plasma norepinephrine levels does represent a decrease in central sympathetic outflow, this observation may explain why verapamil treatment does not cause the reflex increase in heart rate and contractility seen with other vasodilators.
One interpretation of our data is that the increase in lymphocyte /3-receptor responsiveness with verapamil administration is related to the /3-receptor-blocking 
